Targeted Oncology6h
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Yahoo Finance9h
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel ...
The American Journal of Managed Care5h
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Business Wire22h
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
Jazz Pharmaceuticals’ Zepzelca combination meets endpoints in lung cancer trial
Jazz Pharmaceuticals announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca in combination ...
FierceBiotech6h
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
The Pharma Letter10h
FDA approves Novocure’s Optune Lua
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...
Jazz Pharma gains on late-stage trial win for cancer drug
Jazz Pharmaceuticals (JAZZ) stock gains as lung cancer drug Zepzelca with Roche's (RHHBY) Tecentriq hits main goal in Phase 3 ...
emjreviews.com1d
New Imaging Technique Shows Promise for Personalised Oesophageal Cancer Treatment – UEG Week 2024
Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...
Cure Today6d
I Still Reflect on My Lung Cancer Treatment Decisions
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...
Medscape5h
The Long Shots: When Patients Defy All Odds
Oncologists never know which patients with dire prognoses will be among the rare, but real responders. The few who defy all ...
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...